| | Variable | Overall
() | Surgery alone
() | Adjuvant RT
() | value |
| | Patient characteristics | | | | | | Age, yrs. (IQR) | 55 (43, 68) | 55 (43, 69) | 54 (43, 67) | 0.419 | | Female | 1,035 (48%) | 752 (48.1%) | 283 (47.8%) | 0.957 | | Race | | | | 0.792 | | White | 1,774 (84%) | 1,290 (84%) | 484 (84%) | | | Black | 255 (12.1%) | 188 (12.2%) | 67 (11.6%) | | | Other | 83 (3.9%) | 58 (3.8%) | 25 (4.3%) | | | Charlson Comorbidity Score | | | | 0.777 | | 0 | 1,265 (88.6%) | 908 (88.3%) | 357 (89.5%) | | | 1 | 140 (9.8%) | 103 (10%) | 37 (9.3%) | | | ≥2 | 22 (1.5%) | 17 (1.7%) | 5 (1.3%) | | | Education above median | 1,239 (60.9%) | 878 (59.7%) | 361 (63.9%) | 0.091 | | Income above median | 1,406 (69.1%) | 1,005 (68.3%) | 401 (71%) | 0.269 | | Distance to cancer center (IQR) | 13.4 (5.6, 36.4) | 14.7 (5.7, 41.3) | 10.9 (5.1, 24.6) | 0.611 | | Treatment facility | | | | 0.288 | | Community Cancer Program | 117 (5.5%) | 82 (5.4%) | 35 (6%) | | | Comprehensive Community Cancer Program | 827 (39.2%) | 585 (38.3%) | 242 (41.5%) | | | Academic/Research Program | 1,165 (55.2%) | 859 (56.3%) | 306 (52.5%) | | | Uninsured | 76 (3.7%) | 53 (3.5%) | 23 (4%) | 0.697 |
| | Tumor characteristics | | | | | | Limb location | | | | 0.61 | | Upper limb and shoulder | 499 (23.1%) | 367 (23.5%) | 132 (22.3%) | | | Lower limb and hip | 1,658 (76.9%) | 1,198 (76.5%) | 460 (77.7%) | | | Tumor size (mm) | 90 (40, 170) | 84 (35, 170) | 97 (50, 159.2) | 0.504 | | Tumor size | | | | <0.001 | | <5 cm | 582 (31.3%) | 449 (33.9%) | 133 (24.7%) | | | 5–9.9 cm | 406 (21.8%) | 268 (20.2%) | 138 (25.7%) | | | 10–19.9 cm | 527 (28.3%) | 344 (26%) | 183 (34%) | | | >20.0 cm | 347 (18.6%) | 263 (19.9%) | 84 (15.6%) | | | Histology | | | | 0.001 | | Clear cell sarcoma | 4 (0.2%) | 4 (0.3%) | 0 (0%) | | | Epithelioid sarcoma | 8 (0.4%) | 5 (0.3%) | 3 (0.5%) | | | Fibrosarcoma | 91 (4.2%) | 73 (4.7%) | 18 (3%) | | | Leiomyosarcoma | 231 (10.7%) | 185 (11.8%) | 46 (7.8%) | | | Liposarcoma | 1,418 (65.7%) | 1,014 (64.8%) | 404 (68.2%) | | | Malignant fibrous histiocytoma | 103 (4.8%) | 70 (4.5%) | 33 (5.6%) | | | Mixed mesenchymal sarcoma | 3 (0.1%) | 3 (0.2%) | 0 (0%) | | | MPNST | 64 (3%) | 44 (2.8%) | 20 (3.4%) | | | Myxosarcoma | 19 (0.9%) | 9 (0.6%) | 10 (1.7%) | | | Rhabdomyosarcoma | 2 (0.1%) | 1 (0.1%) | 1 (0.2%) | | | Sarcoma NOS | 122 (5.7%) | 98 (6.3%) | 24 (4.1%) | | | Small cell sarcoma | 2 (0.1%) | 0 (0%) | 2 (0.3%) | | | Spindle cell sarcoma | 45 (2.1%) | 33 (2.1%) | 12 (2%) | | | Synovial sarcoma | 44 (2%) | 25 (1.6%) | 19 (3.2%) | | | Undifferentiated sarcoma | 1 (0%) | 1 (0.1%) | 0 (0%) | |
| | Treatment specifics | | | | | | Surgery type | | | | 0.002 | | Local excision | 723 (33.5%) | 525 (33.5%) | 198 (33.4%) | | | Radication resection | 1,365 (63.3%) | 976 (62.4%) | 389 (65.7%) | | | Limb amputation | 65 (3%) | 60 (3.8%) | 5 (0.8%) | | | Major amputation | 4 (0.2%) | 4 (0.3%) | 0 (0%) | | | Amputation (versus no amputation) | 69 (3.2%) | 64 (4.1%) | 5 (0.8%) | <0.001 | | Days to definitive surgery (IQR) | 0 (0, 34) | 0 (0, 33) | 10 (0, 35.2) | 0.598 | | Neoadjuvant chemo | 1 (0.3%) | 0 (0%) | 1 (1.2%) | 0.256 | | Adjuvant chemo | 6 (1.8%) | 1 (0.4%) | 5 (6%) | 0.005 |
| | Endpoints and outcomes | | | | | | Surgical margins | | | | 0.001 | | Negative | 1,534 (78.5%) | 1,133 (80.5%) | 401 (73.3%) | | | Microscopic | 234 (12%) | 146 (10.4%) | 88 (16.1%) | | | Macroscopic | 186 (9.5%) | 128 (9.1%) | 58 (10.6%) | | | 30-day readmission | 35 (2.6%) | 27 (2.7%) | 8 (2.1%) | 0.626 | | Hospital LOS (IQR) | 1 (0, 3) | 1 (0, 3) | 1 (0, 3) | 0.427 |
|
|
